Giorgi, U. D., Agarwal, N., Shore, N. D., Barata, P. C., Fizazi, K. O., Matsubara, N., Zschaebitz, S., Carles, J., Fay, A. P., Zielinski, M. A., Wang, F., Lin, X., Messina, R., Azad, A. (2026). Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: Extended follow-up.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5043